The Burden Associated with Ocular Symptoms in Allergic Rhinitis

Klossek, Jean‐Michel; Annesi‐Maesano, Isabella; Pribil, C.; Didier, A.

doi:10.1159/000334286

Cited by 41 publications

(28 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This analysis is pertinent since it is important to show efficacy in patients irrespective of symptom severity. A symptomatic subgroup of patients was defined with rTOSS baseline ≥8 to define patients with at least moderate ocular symptoms, since ocular symptoms are often not quantified even though they affect most subjects with SAR [25]. A reflective total of 5 symptom scores (rT5SS; rTNSS plus ocular itching) and a reflective total of 7 symptom scores (rT7SS; rTNSS plus rTOSS) were also determined, and change from baseline was assessed by the same ANCOVA model, as patients frequently present to clinic with both nasal and ocular symptoms.…”

Section: Methodsmentioning

confidence: 99%

Clinically Relevant Effect of a New Intranasal Therapy (MP29-02) in Allergic Rhinitis Assessed by Responder Analysis

Meltzer

Ratner

Bachert

et al. 2013

Int Arch Allergy Immunol

102

137

View full text Add to dashboard Cite

Background: It is unclear what constitutes a clinically meaningful response for allergic rhinitis (AR) outcomes. The objectives of these post hoc analyses were (1) to define a clinically meaningful response using novel efficacy analyses (including a responder analysis), and (2) to compare the efficacy of MP29-02 [a novel intranasal formulation of azelastine hydrochloride (AZE) and fluticasone propionate (FP)] with commercially available FP, AZE and placebo in seasonal AR (SAR) patients, using these novel analyses. Methods: 610 moderate-to-severe SAR patients (≥12 years old) were randomized into a double-blind, placebo-controlled, 14-day, parallel-group trial. Change from baseline in the reflective total nasal symptom score (rTNSS) over 14 days was the primary outcome. Post hoc endpoints included the sum of nasal and ocular symptoms (rT7SS), efficacy by disease severity and by predominant nasal symptom, and a set of responder analyses. Results: MP29-02 most effectively reduced rT7SS (relative greater improvement: 52% to FP; 56% to AZE) and both nasal and ocular symptoms irrespective of severity. More MP29-02 patients achieved a ≥30, ≥50, ≥60, ≥75 and ≥90% rTNSS reduction, which occurred days faster than with either active comparator; MP29-02 alone was superior to placebo at the ≥60% (or higher) threshold. One in 2 MP29-02 patients achieved a ≥50% rTNSS reduction and 1 in 6 achieved complete/near-to-complete response. Only MP29-02 was consistently superior to placebo for all patients, whatever their predominant symptom. Conclusions: MP29-02 provided faster and more complete symptom control than first-line therapies. It was consistently superior irrespective of severity, response criteria or patient-type, and may be considered the drug of choice for moderate-to-severe AR. These measures define a new standard for assessing relevance in AR.

show abstract

Section: Methodsmentioning

confidence: 99%

Clinically Relevant Effect of a New Intranasal Therapy (MP29-02) in Allergic Rhinitis Assessed by Responder Analysis

Meltzer

Ratner

Bachert

et al. 2013

Int Arch Allergy Immunol

102

137

View full text Add to dashboard Cite

show abstract

“…However, allergic rhinoconjunctivitis should not be overlooked. Indeed, in a large survey ocular symptoms among allergic rhinitis patients were triggered by house dust and HDM in 34.8% [130]. The study reported a substantial impact of eye symptoms on daily life.…”

Section: Clinical Pictures: Asthma Rhinitis/rhinosinusitis Atopic Dmentioning

confidence: 99%

International consensus (ICON) on: clinical consequences of mite hypersensitivity, a global problem

Sánchez‐Borges

Fernández-Caldas

Thomas

et al. 2017

World Allergy Organization Journal

View full text Add to dashboard Cite

Since mite allergens are the most relevant inducers of allergic diseases worldwide, resulting in significant morbidity and increased burden on health services, the International Collaboration in Asthma, Allergy and Immunology (iCAALL), formed by the American Academy of Allergy, Asthma and Immunology (AAAAI), the American College of Allergy, Asthma and Immunology (ACAAI), the European Academy of Allergy and Clinical Immunology (EAACI), and the World Allergy Organization (WAO), has proposed to issue an International Consensus (ICON) on the clinical consequences of mite hypersensitivity. The objectives of this document are to highlight aspects of mite biology that are clinically relevant, to update the current knowledge on mite allergens, routes of sensitization, the genetics of IgE responses to mites, the epidemiologic aspects of mite hypersensitivity, the clinical pictures induced by mites, the diagnosis, specific immunotherapeutic approaches, and prevention.

show abstract

“…In a French, cross-sectional observational survey, 31% of the population-based sample suffered from allergic rhinitis and 52% of patients with allergic rhinitis described ocular symptoms, with 57% of subjects suffering from ocular symptoms for more than 5 years, mostly (92%) during the pollen season [11]. Similarly, a survey on 447 patients with allergic rhinitis revealed that 64% of patients experienced itchy/red eyes, whereas 43% reported watery eyes [12], demonstrating that ocular allergy is part of the burden associated with allergic rhinitis.…”

Section: Key Pointsmentioning

confidence: 99%